These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 23177289)

  • 1. Cyclophilin inhibitors for hepatitis C therapy.
    Membreno FE; Espinales JC; Lawitz EJ
    Clin Liver Dis; 2013 Feb; 17(1):129-39. PubMed ID: 23177289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The end of the beginning for hepatitis C treatment.
    Dieterich D
    Hepatology; 2012 Mar; 55(3):664-5. PubMed ID: 22174100
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of hepatitis C virus genotype 3-infection.
    Pol S; Vallet-Pichard A; Corouge M
    Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral treatment of hepatitis C.
    Feeney ER; Chung RT
    BMJ; 2014 Jul; 348():g3308. PubMed ID: 25002352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
    Welch NM; Jensen DM
    Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV NS5A inhibitors in development.
    Suk-Fong Lok A
    Clin Liver Dis; 2013 Feb; 17(1):111-21. PubMed ID: 23177287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutic strategies in HCV: second-generation protease inhibitors.
    Clark VC; Peter JA; Nelson DR
    Liver Int; 2013 Feb; 33 Suppl 1():80-4. PubMed ID: 23286850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
    Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon free therapy with direct acting antivirals for HCV.
    Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C drug development at a crossroads.
    Nelson DR
    Hepatology; 2009 Oct; 50(4):997-9. PubMed ID: 19787813
    [No Abstract]   [Full Text] [Related]  

  • 12. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
    Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
    Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophilin inhibitors.
    Gallay PA
    Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C?
    Wedemeyer H
    Nat Rev Gastroenterol Hepatol; 2013 Feb; 10(2):76-8. PubMed ID: 23296251
    [No Abstract]   [Full Text] [Related]  

  • 16. Mixing and matching drugs: what makes sense?
    Welzel TM; Zeuzem S
    Clin Liver Dis; 2011 Aug; 15(3):657-64. PubMed ID: 21867943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X; Lawitz E; Zeuzem S; Gane E; Bronowicki JP; Andreone P; Horban A; Brown A; Peeters M; Lenz O; Ouwerkerk-Mahadevan S; Scott J; De La Rosa G; Kalmeijer R; Sinha R; Beumont-Mauviel M
    Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
    Tornai I
    Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
    Chayama K; Takahashi S; Toyota J; Karino Y; Ikeda K; Ishikawa H; Watanabe H; McPhee F; Hughes E; Kumada H
    Hepatology; 2012 Mar; 55(3):742-8. PubMed ID: 21987462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors.
    Puyang X; Poulin DL; Mathy JE; Anderson LJ; Ma S; Fang Z; Zhu S; Lin K; Fujimoto R; Compton T; Wiedmann B
    Antimicrob Agents Chemother; 2010 May; 54(5):1981-7. PubMed ID: 20176894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.